WuXi AppTec Delivers Strong Q1-Q3 2026 Results and Further Raises Full-Year Guidance, Driven by Greater Success of Multiple Customers’ Products and CRDMO Model

  • Post author:
  • Post category:Business

SHANGHAI, Oct. 26, 2026 /PRNewswire/ -- WuXi AppTec (Stock Codes: 603259.SH / 2359.HK), a leading global pharmaceutical CRDMO (Contract Research, Development, and Manufacturing Organization), today announced financial results for the first three quarters ending September 30, 2026 ("Reporting…

Continue ReadingWuXi AppTec Delivers Strong Q1-Q3 2026 Results and Further Raises Full-Year Guidance, Driven by Greater Success of Multiple Customers’ Products and CRDMO Model

Guosen Securities Outlines Priorities for China’s Capital Markets Under 15th Five-Year Plan

  • Post author:
  • Post category:Business

Market stability, support for innovation and stronger regulatory oversight to shape capital market development through 2030SHENZHEN, China, Oct. 26, 2026 /PRNewswire/ -- Guosen Securities, one of China's leading securities firms and investment banks, expects the country's capital markets…

Continue ReadingGuosen Securities Outlines Priorities for China’s Capital Markets Under 15th Five-Year Plan

Bitfire Group Reports Q3 Digital Assets Under Management of US$221 Million, Up 60.1%

Crypto-asset trading volume rises 362.2% to US$342 million, while client base expands 31.4% to 1,058HONG KONG, Oct. 26, 2026 /PRNewswire/ -- Bitfire Group Holdings Limited (HKEX: 1611), formerly known as Sinohope Technology Holdings Limited (the "Company" or the…

Continue ReadingBitfire Group Reports Q3 Digital Assets Under Management of US$221 Million, Up 60.1%

ESMO 2026 | Professors Jie Wang, Zhijie Wang and Jianchun Duan’s Team Reports 95.2% Disease Control With LK101 Combination Maintenance Therapy in Advanced NSCLC

  • Post author:
  • Post category:Sales & Growth

BEIJING, Oct. 25, 2026 /PRNewswire/ -- On October 24, 2026, in Madrid, Spain, the team of Professors Jie Wang, Zhijie Wang and Jianchun Duan at the Cancer Hospital, Chinese Academy of Medical Sciences, presented Phase 1b/2a results in a…

Continue ReadingESMO 2026 | Professors Jie Wang, Zhijie Wang and Jianchun Duan’s Team Reports 95.2% Disease Control With LK101 Combination Maintenance Therapy in Advanced NSCLC

Ascletis Announces FDA IND Submission of ASC39, an Oral Small Molecule Selective Amylin Receptor Agonist for the Treatment of Obesity

  • Post author:
  • Post category:Sales & Growth

- ASC39, an oral small molecule selective amylin receptor agonist, demonstrated eloralintide-like amylin selectivity and efficacy in preclinical models.- ASC39 demonstrated eloralintide-like selectivity for human amylin 1 receptor (hAMY1R) over human calcitonin receptor (hCTR) (40-fold), supporting the potential…

Continue ReadingAscletis Announces FDA IND Submission of ASC39, an Oral Small Molecule Selective Amylin Receptor Agonist for the Treatment of Obesity